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• Body height and prothrombotic genotypes are associated with risk of venous thromboembolism (VTE).
• The joint effect of prothrombotic genotypes and tall stature on VTE risk is scarcely investigated.
• We investigated the joint effect of prothrombotic genotypes and tall stature on VTE risk.
• Prothrombotic genotypes did not yield excess risk of VTE in subjects with a tall stature.
Summary. Background: Studies have reported synergistic effects of prothrombotic single-nucleotide polymorphisms (SNPs) and obesity on the risk of venous thromboembolism (VTE). Tall stature is associated with an increased VTE risk, but the joint effect of prothrombotic genotypes and tall stature on the VTE risk is unknown. Aims: To investigate the joint effects of prothrombotic genotypes and tall stature on the VTE risk. Methods: Cases with incident VTE (n = 676) and a randomly selected ageweighted subcohort (n = 1842) were sampled from the Tromsø study (cohort follow-up: 1994-2012). DNA was genotyped for rs6025 (factor V Leiden), rs1799963 (FII), rs8176719 (ABO blood group), rs2066865 (fibrinogen-c), and rs2036914 (FIX). Age-adjusted and sex-adjusted hazard ratios (HRs) of VTE were calculated by categories of risk alleles (de Haan 5-SNP score: 0-1, 2-3, and ≥ 4) and body height (< 40th, 40th-80th and > 80th percentiles). Results: The VTE risk increased by increasing category of body height, and subjects with height ≥ 178 cm had a two-fold higher VTE risk (HR 2.03; 95% confidence interval [CI] 1.51-2.73) than those with height ≤ 165 cm. The VTE risk also increased across categories of risk alleles. However, the combination of a tall stature and risk alleles, either individual SNPs or risk score, did not result in an excess VTE risk. Subjects with four or more risk alleles and height ≥ 178 cm had a two-fold
Introduction
Venous thromboembolism (VTE) is a common and potentially fatal disease with a complex, multicausal etiology [1] . Anthropometric measures, such as obesity and body height, are both recognized as being consistent and substantial risk factors for VTE. Obesity is associated with a two-fold to three-fold increased VTE risk [2] [3] [4] , and, although waist circumference may identify the highest proportion at VTE risk [5] , the association between obesity and VTE holds true for all measures of body composition [5] [6] [7] . A tall stature is associated with the risk of both first [3, 8, 9] and recurrent [9, 10] VTE. In a previous report from the Tromsø study, we showed that the risk of a first-lifetime VTE increased by 34% per 10-cm increase in body height, and that men with a tall stature (> 181 cm) had a two-fold higher VTE risk than men with a short stature (< 173 cm) [8] . Furthermore, the combination of a tall stature and obesity had a synergistic effect on the VTE risk, resulting in a five-fold higher risk [11] . Vessel wall damage, changes in blood flow and hypercoagulability are the three important elements in the pathogenesis of thrombosis [12] . The mechanisms by which obesity and tall stature increase VTE risk remain unsettled. Obesity may facilitate thrombosis risk by attenuating the velocity of venous blood return (changes in blood flow) and increasing the hydrostatic pressure (damage to vessel walls) owing to increased abdominal pressure [13] . Moreover, proinflammatory mechanisms effects of the adipose tissue itself may promote a prothrombotic state [14] [15] [16] . Regarding body height, a predisposition to thrombosis in people with a tall stature may involve a greater venous surface area and damage to the vessel wall resulting from higher hydrostatic pressure during standing (damage to vessel walls) and a longer time being needed to achieve minimal venous pressure during exercise (changes in flow) [17] .
In recent years, several single-nucleotide polymorphisms (SNPs) have been identified as VTE risk factors [18] , and multiple SNP testing, including genetic risk scores, has been shown to improve the risk prediction of first-time VTE [19] . Established prothrombotic genotypes such as factor V Leiden (FVL), F2 G20210A, and blood group non-O, have been reported to substantially increase the VTE risk in overweight and obese individuals [4, [20] [21] [22] , resulting in an excess number of VTE cases because of the biological interaction. To what extent the combination of a tall stature and prothrombotic genotypes impacts on the VTE risk has not been studied. Therefore, we aimed to investigate the joint effects of genetic risk factors and a tall stature on the VTE risk in a case-cohort recruited from the general population.
Materials and methods

Study population
As previously described in detail [23] , the Tromsø study is a single-center, prospective, population-based cohort, with repeated health surveys of inhabitants in Tromsø, Norway. In the present study, participants were recruited from the fourth (1994) (1995) , fifth (2001) (2002) and sixth (2007) (2008) surveys. Members of the population aged > 25 years living in the municipality of Tromsø, Norway, were invited to participate in these surveys. The overall participation rate was high, ranging from 77% in Tromsø 4 to 66% in Tromsø 6. All subjects (n = 30 371) were followed from the date of inclusion in these surveys until an adjudicated incident VTE event, migration, death, or end of follow-up (31 December 2012). All firstlifetime VTE events occurring among the participants in this period were identified from the hospital discharge diagnosis registry, the autopsy registry and the radiology procedure registry from the University Hospital of North Norway, which is the sole provider of diagnostic radiology and treatment for VTE in the Tromsø area. Trained personnel adjudicated and recorded each VTE by extensive medical record review. The adjudication criteria for VTE were the presence of signs and symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT) combined with objective confirmation by radiologic procedures that resulted in treatment initiation (unless contraindications were specified). The identification and adjudication process for VTEs has been previously described in detail [8] .
A total of 737 individuals experienced a VTE during follow-up. Of these, 39 did not have blood samples available or of sufficient quality for DNA analysis. Thus, the remaining 692 subjects were included as cases in our study. A subcohort (n = 2016) was created by randomly sampling participants from the fourth, fifth and sixth surveys of the Tromsø study weighted for the age of the cases in 5-year age groups. Because of the case-cohort design, 71 of the cases were also sampled and included in the subcohort. Subjects with missing values for body height or weight (n = 5) or any of the SNPs of interest (n = 186, VTE = 16) were excluded, yielding a case-cohort of 676 VTE cases and 1842 subcohort members. The study was approved by the Regional Committee of Medical and Health Research Ethics (REC North), and all participants gave their informed written consent to participate.
Measurements
Baseline information was collected by the use of physical examination, non-fasting blood samples, and self-administered questionnaires. Body height (measured to the nearest centimeter in Tromsø 4 and to the nearest 0.5 cm in Tromsø 5 and Tromsø 6) and body weight (measured to the nearest kilogram in Tromsø 4 and to the nearest 0.1 kg in Tromsø 5 and Tromsø 6) was assessed with subjects wearing short-sleeved garments and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg m
À2
).
Genotyping and quality control
We genotyped the SNPs rs6025 (FVL), rs1799963 (FII [F2]), rs8176719 (ABO blood group), and rs2036914 (FIX [F11]), with the Sequenom platform, and rs2066865 (fibrinogen-c [FGG]) with the TaqMan platform. For Sequenom, which uses single-base extension followed by mass spectrometry to measure the molecular mass of the extended primers, samples were genotyped with the Sequenom iPlex Gold Assay according to the recommended protocol, with an initial input of 10-20 ng of DNA, and were analyzed with the MassARRAY Analyzer 4. Only genotypes with a high quality score of 'A. Conservative' or 'B. Moderate' were used. When multiple attempts were made to genotype an individual, one of the highest-quality genotypes across all attempts was chosen for each SNP. For TaqMan, an initial input of 100 ng of DNA was used. Samples were genotyped with the Applied Biosystems 7900HT (Foster City, CA, USA) according to the recommended protocol, and processed with SDS 2.4 (Thermo Fisher, Foster City, CA, USA); genotypes passing a quality value threshold of 95 were used.
Statistical analyses
Statistical analyses were performed with STATA version 14 (StataCorp LP, College Station, TX, USA). Follow-up time was calculated from the date of inclusion until a VTE event, migration, death, or study end (31 December 2012).
Body height was categorized according to the < 40th, 40th-80th and ≥ 80th percentile cut-offs among the subcohort members (≤ 165 cm, 166-177 cm, and ≥ 178 cm). Cox proportional hazards regression models with age as timescale were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE across categories of body height. Moreover, the HRs of VTE according to the heterozygous or homozygous forms of each SNP were assessed within categories of body height. The proportional hazards assumption was verified by evaluating the parallelism between the curves of the log-log survivor function for different categories of the variables.
On the basis of the article by De Haan et al. [19] , we composed a '5-SNP genetic burden model' by summarizing the number of risk alleles from the five sequenced SNPs. Using this model, we assessed the VTE risk per one risk allele increase, and across categories of increasing numbers of risk alleles (0-1, 2-3 and ≥ 4 risk alleles) with the 0-1 category as reference. Next, we repeated these analyses stratified for height categories. Finally, to investigate potential synergistic effects of genetic burden and height on the VTE risk, we combined categories of height and genetic burden, and conducted a Cox regression on subjects with the shortest stature and lowest number of risk alleles as reference. Biological interaction and synergism were evaluated by use of the Rothman synergy index [24] to determine whether the joint effects of a tall stature and high genetic burden (≥ 4 risk alleles) on the VTE risk exceeded the sum of effects from each factor alone. The synergy indexes with corresponding 95% CIs were calculated according to Andersson et al. [25] , with an Excel sheet (epinet.se/res/xls/ epinetcalculation.xls). A synergy index of > 1.0 suggests that the effect of joint exposure to two risk factors is greater than the sum of the separate effects.
Results
The baseline characteristics of the cases and the subcohort are shown in Table 1 . The distribution of age, sex and cardiovascular risk factors was similar among cases and subcohort members. The allele frequencies of the different SNPs in the subcohort were similar to those previously reported in Scandinavian populations.
The VTE risk increased across categories of body height (Fig. 1, Table S1 ). Subjects in the middle category of body height (166-177 cm) had a 1.4-fold higher VTE risk (HR 1.41; 95% CI 1.14-1.73) and subjects in the upper category (≥ 178 cm) had a two-fold higher VTE risk (HR 2.04; 95% CI 1.51-2.74) than those in the lower category (≤ 165 cm) (Fig. 1) . The distribution of number of risk alleles among cases and subcohort members according to the 5-SNP model is shown in Fig. 2 . The VTE risk increased in a 'dose-response' manner across increasing number of risk alleles in this model (Fig. 2 , Table S2 ).
The combined effect of prothrombotic genotypes (individual SNPs) and body height on the VTE risk is shown in Table 2 . Within all categories of body height, the VTE risk was increased approximately two-fold in those with one FVL risk allele. However, the combined effect of FVL risk alleles and a tall stature did not exceed the sum of the effects of the individual components, indicating no biological interaction between these two. In fact, there was no indication of synergistic effects between the individual SNPs and increasing body height ( Table 2 ). The 5-SNP score was associated with the VTE risk only in the two lower body height quintiles, in which the presence of ≥ 4 risk alleles was associated with a 1.6-fold (HR 1.57; 95% CI 1.07-2.31) and a 2.3-fold (HR 2.32; 95% CI 1.59-3.37) increased VTE risk, respectively (Fig. 3) . In the upper body height category, there was no increased risk in those with ≥ 4 risk alleles (HR 1.03; 95% CI 0.60-1.77). The VTE risk was only two-fold higher in those with ≥ 4 risk alleles and a tall stature than in those with 0-1 risk alleles and a short stature (HR 2.08; 95% CI 1.24-3.52). Consequently, the combination of ≥ 4 risk alleles and a tall stature did not have any synergistic impact on the VTE risk (synergy index: 0.71, 95% CI 0.28-1.76).
Discussion
In the present study, we aimed to assess the combined effect of prothrombotic genotypes and body height on the VTE risk. When we investigated body height and prothrombotic genotypes separately, we found that both were associated with an increased VTE risk. However, the presence of prothrombotic genotypes, either as individual SNPs or as genetic risk score, did not increase the VTE risk in those with a tall stature, and consequently the combination of a tall stature and prothrombotic SNPs did not have any synergistic effect on the VTE risk.
To our knowledge, no study has previously investigated the combined effects of prothrombotic genotypes and body height on the VTE risk. The finding of no biological interaction between prothrombotic genotypes and a tall stature is in contrast to findings for other anthropometric features, such as obesity. In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study, obese subjects with one or more FVL risk alleles had an almost eight-fold higher VTE risk than normal-weight subjects with no risk alleles [4] . Several studies have confirmed the interaction between obesity and FVL [4, 20, 21, 26] , and an excessive VTE risk has additionally been reported for the combination of obesity and prothrombin G20210A [4, 21] or blood type O [20] . CI, confidence interval; FGG, fibrinogen-c; FVL, factor V Leiden; HR, hazard ratio. Adjusted for age (as timescale) and sex (as covariate).
*HRs within strata of body height. †HRs across strata of body height.
The mechanisms behind the increased VTE risk in subjects with a tall stature are thought to involve alteration of venous flow parameters and venous stasis in long legs [17, 27] . Moreover, a larger venous surface area or a higher number of venous valves may result in a predisposition for thrombus formation in tall people. Obesity is also associated with venous stasis [13] , and may thereby predispose subjects to developing VTE. However, obesity is additionally associated with a state of chronic lowgrade inflammation, and may contribute to thrombosis risk via other mechanisms, such as increased platelet hyperactivity [28] and alterations in the coagulation and fibrinolytic systems [28, 29] . These mechanisms may, to a large extent, be influenced by genetic risk factors, as prothrombotic variants are mostly related to pathways in the coagulation system [18] . As suggested by Christiansen et al. [20] , the observation that obesity, FVL and blood group non-O are all associated with increased levels of FVIII or activated protein C resistance provides biological plausibility for a synergistic effect.
Our finding of no synergism between prothrombotic genotypes and a tall stature may indicate that body height and obesity influence the VTE risk by different pathophysiologic mechanisms. Studies have shown that the relationship between obesity and VTE is partially mediated by inflammation [16, 30] . In the Longitudinal Investigation of Thromboembolism Etiology (LITE) study [7] , BMI was associated with increased levels of C-reactive protein and coagulation factors such as FVII, FVIII, and fibrinogen, whereas body height was inversely associated with the same factors. These findings suggest that venous stasis and vessel wall damage, rather than hypercoagulability, constitute the underlying mechanism for the effect on VTE risk of tall stature. Although a biological interaction between obesity and prothrombotic genotypes may induce a hypercoagulable state that could potentially explain the excess VTE risk, the lack of association between height and inflammation and/or coagulation may explain why such a joint effect was not observed in those with a tall stature and prothrombotic genotypes.
The strengths of our study include the well-validated cases and subcohort recruited from an adult general population followed over a long period. Both body height and prothrombotic genotypes were objectively measured before the VTE events occurred, and, as body height generally does not change much over time, regression dilution effects attributable to long follow-up would be negligible. The study was limited by a low number of events in some subgroups, particularly for genetic variants with a low prevalence of homozygous individuals, and the risk estimates in these subgroups must therefore be interpreted with some caution. Moreover, we cannot rule out a potential synergistic effect in individuals who were homozygous for FVL or F2, owing to a lack of events in these categories. The risks of various types of VTE (i.e. DVT/PE) may differ according to genetic predisposition (e.g. the FVL paradox). Unfortunately, we did not have sufficient statistical power to perform subgroup analyses with DVT and PE, or unprovoked and provoked VTE, as outcomes.
In conclusion, increased body height and number of prothrombotic risk alleles were associated with an increased VTE risk when they were investigated separately. However, the combination of a tall stature and prothrombotic genotypes did not result in an excess VTE risk, suggesting that there is no biological interaction between taller height and a genetic predisposition to develop VTE. 
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